CALIDI BIOTHERAPEUTICS INC (CLDI)
US3207031010 - Common Stock
Overall CLDI gets a fundamental rating of 0 out of 10. We evaluated CLDI against 586 industry peers in the Biotechnology industry. CLDI may be in some trouble as it scores bad on both profitability and health. CLDI is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
CLDI had negative earnings in the past year.
1.2 Ratios
With a Return On Assets value of -126.83%, CLDI is not doing good in the industry: 83.93% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -126.83% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-576.69%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for CLDI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CLDI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CLDI has about the same amount of shares outstanding.
CLDI has a worse debt/assets ratio than last year.
2.2 Solvency
CLDI has an Altman-Z score of -10.36. This is a bad value and indicates that CLDI is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -10.36, CLDI is doing worse than 78.46% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -10.36 |
ROIC/WACCN/A
WACC6.36%
2.3 Liquidity
CLDI has a Current Ratio of 1.07. This is a normal value and indicates that CLDI is financially healthy and should not expect problems in meeting its short term obligations.
CLDI has a Current ratio of 1.07. This is amonst the worse of the industry: CLDI underperforms 88.72% of its industry peers.
A Quick Ratio of 1.07 indicates that CLDI should not have too much problems paying its short term obligations.
CLDI's Quick ratio of 1.07 is on the low side compared to the rest of the industry. CLDI is outperformed by 87.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.07 | ||
| Quick Ratio | 1.07 |
3. Growth
3.1 Past
CLDI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -132.57%.
CLDI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -89.98%.
EPS 1Y (TTM)-132.57%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2QN/A
Revenue 1Y (TTM)-89.98%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
CLDI is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -4.74% yearly.
Based on estimates for the next years, CLDI will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y-155.26%
EPS Next 2Y-30.92%
EPS Next 3Y-4.73%
EPS Next 5Y-4.74%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CLDI. In the last year negative earnings were reported.
Also next year CLDI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as CLDI's earnings are expected to decrease with -4.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-30.92%
EPS Next 3Y-4.73%
5. Dividend
5.1 Amount
CLDI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CALIDI BIOTHERAPEUTICS INC
NYSEARCA:CLDI (5/17/2024, 7:04:02 PM)
After market: 0.235 +0.01 (+3.3%)0.2275
-0.01 (-5.99%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap11.58M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -126.83% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.07 | ||
| Quick Ratio | 1.07 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-132.57%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-155.26%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-89.98%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y